Crossbow Therapeutics, Inc is a company.
Key people at Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc was founded by Geraldine Paulus (Co-founder, Head of Corporate Development and Strategy).
Key people at Crossbow Therapeutics, Inc.
Crossbow Therapeutics, Inc was founded by Geraldine Paulus (Co-founder, Head of Corporate Development and Strategy).
Crossbow Therapeutics, Inc. is an early-stage biotechnology company developing next-generation T-cell engagers called T-Bolt molecules, which are T-cell receptor mimetic (TCRm) antibodies targeting peptide-HLA (pHLA) complexes on cancer cells to enable precise destruction of tumors.[1][2][3][5] These therapies address intracellular cancer antigens previously inaccessible to traditional antibodies, serving patients with various cancers including myeloid malignancies and those driven by telomerase, with a rich pipeline in development.[1][2][5] The company, founded in 2021 and headquartered in Cambridge, Massachusetts, raised $80M in a Series A round in 2023, showing strong early momentum with FDA acceptance of its first IND for CBX-250 in April 2025 and a second program advancing to IND-enabling studies.[1][2][5]
Crossbow Therapeutics was founded in 2021 and incubated by MPM BioImpact, emerging from stealth in July 2023 with an $80M Series A financing co-led by MPM and Pfizer Ventures.[1][5] The leadership team includes CEO Briggs Morrison, M.D., an experienced drug developer, and Chief Scientific Officer Dmitri Wiederschain, Ph.D., supported by a "top-tier, well-rounded" group of experts in drug discovery, development, and company building.[2][5] Key early milestones include selecting the first development candidate in March 2024, forming a Scientific Advisory Board in October 2023, and achieving FDA IND acceptance for CBX-250—a T-cell engager for a tumor-specific target in myeloid malignancies—with first patient dosing projected for summer 2025.[2][5] This rapid progress reflects the team's focus on scaling TCR-mimicking strategies for broad cancer applicability.[1]
Crossbow stands out in cancer immunotherapy through these key strengths:
Crossbow is riding the surge in precision oncology and T-cell engager therapies, scaling up TCR-mimicking approaches pioneered by companies like Immunocore to unlock intracellular targets, which represent a vast untapped antigen space.[1] Timing is ideal amid growing demand for next-gen immunotherapies post-checkpoint inhibitors, fueled by advances in antigen discovery and bispecific engineering that widen the target funnel for patient populations.[1][2] Favorable market forces include regulatory momentum (e.g., rapid IND clearances) and investor interest in scalable platforms addressing unmet needs in solid tumors and hematologic cancers, positioning Crossbow to influence the ecosystem by partnering and broadening immunotherapy's reach.[2][5]
Crossbow's near-term catalysts include first patient dosing for CBX-250 this summer, IND progress for its telomerase program, and pipeline expansions, potentially driving Series B funding or partnerships amid a robust biotech funding recovery.[2][5] Trends like AI-enabled antigen validation and multi-specific engagers will accelerate their platform, evolving Crossbow from stealth innovator to a leader in intracellular targeting—ultimately revolutionizing cancer treatment's precision and scope, as their T-Bolt molecules strike at the heart of tumors.[1][5]
